Atara Biotherapeutics, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 10, 2026, covering the fiscal quarter ended September 30, 2026, and reporting 10,188,438 shares of common stock outstanding as of November 6, 2026.
Key Highlights
- Shares outstanding: 10,188,438 shares of common stock were outstanding as of November 6, 2026, according to the filing.
- Smaller reporting company: The company is classified as a non-accelerated filer and a smaller reporting company, as indicated on the cover page.
- One approved product: The filing states the company has one approved product, Ebvallo, authorized in the European Economic Area, the United Kingdom, and Switzerland.
- Strategic alternatives review: The filing discloses that the company is reviewing strategic alternatives, including the possibility that the board may pursue liquidation, dissolution, or other wind-down of the business.
- Going concern risk: The company disclosed a need for "substantial near-term financing to continue operations" and noted that failure to obtain capital could force delays, reductions, or termination of operations.
- HCR Molag agreement: The filing references a Purchase and Sale Agreement, as amended, with HCR Molag Fund, L.P., relating to Ebvallo royalties and milestones in the UK, EEA, and Switzerland.
Atara Biotherapeutics Discloses Strategic Uncertainty and Capital Needs in September 2026 Quarterly Report
Atara Biotherapeutics, Inc. (NASDAQ:ATRA), based in Thousand Oaks, California, submitted its Form 10-Q for the quarterly period ended September 30, 2026. The filing identifies the company's sole approved product as Ebvallo (tab-cel), which holds regulatory authorization in the European Economic Area, the United Kingdom, and Switzerland. Commercialization of Ebvallo in those markets is conducted under an amended and restated Commercialization Agreement with Pierre Fabre Medicament, with the related royalty and milestone economics in the UK, EEA, and Switzerland subject to a Purchase and Sale Agreement with HCR Molag Fund, L.P., as amended.
The company disclosed that it is actively reviewing strategic alternatives, and noted that "our board of directors may determine to pursue a liquidation and dissolution or other wind down of our business." The filing adds that "the amount of cash available for distribution to our stockholders, if any, will depend heavily on the timing of such liquidation as well as the amount of cash that will need to be reserved for commitments and contingent liabilities." The company also disclosed that it "has incurred substantial losses since our inception" and anticipates continuing to do so for the foreseeable future.
Regarding capital resources, the filing states the company "will require substantial near-term financing to continue operations," and that failure to secure capital could force delays or termination of product development, impair exploration of strategic alternatives, or require a wind-down. The filing contains forward-looking statements subject to the company's cautionary language, including statements about BLA timing for tab-cel for patients with Epstein-Barr virus positive post-transplant lymphoproliferative disease, commercialization expectations, and regulatory submissions. Those statements are the company's own projections and are subject to known and unknown risks and uncertainties as described in Item 1A of the filing.
What Was Disclosed
Atara Biotherapeutics filed a Form 10-Q for the quarter ended September 30, 2026, disclosing 10,188,438 shares outstanding, one approved product (Ebvallo), an ongoing strategic alternatives review including possible liquidation, and a stated need for near-term financing to continue operations.



Please wait processing your request...